Cypre

Cypre is a private, preclinical-stage biotech platform company founded in 2020, operating in the AI/Machine Learning and Drug Delivery sectors with a focus on oncology. Its core offering is a sophisticated 3D tumor microenvironment (TME) platform, built on proprietary VersaGel® and Symphony® hydrogels, designed to reduce reliance on animal studies and improve clinical predictability for therapies like ADCs, T-cell engagers, and immunotherapies. The company employs a partnership-driven business model, offering both translational research services and integrated drug discovery collaborations to generate IND-ready data packages for its clients. Cypre is positioned to capitalize on the growing demand for human-relevant, high-throughput preclinical models amid increasing regulatory scrutiny of animal data.

Proprietary 3D tumor organoid platform featuring a tunable VersaGel® hydrogel matrix that integrates patient-derived tumor cells, human stromal components (fibroblasts, ECM), and immune cells (T cells, macrophages, etc.) to model the human tumor microenvironment. The platform enables high-resolution MOA analytics via high-content imaging, cytokine profiling, and flow cytometry, supported by AI/ML data analysis.

Cypre competes in the advanced preclinical models space against other organoid and 3D cell culture companies (e.g., Crown Bioscience, Cellesce, Emulate), as well as the internal efforts of large pharmaceutical companies and CROs. Its differentiation lies in the explicit, tunable 3-tiered integration of tumor, stroma, and immune components within a proprietary hydrogel, combined with a partnership model that spans from discovery to IND support.